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The COL4A5 gene in Japanese Alport syndrome patients: Spectrum of
mutations of all exons. To determine the spectrum of mutations of the
COL4A5 gene encoding type IV colIagen among Japanese Alport syn-
drome (AS) patients, 60 unrelated patients (47 males and 13 females)
from alI over the country were recruited. Screening for mutations in alI the
exons (1 to 51) of the COL4A5 gene was carried out by PCR-SSCP
analysis. A mobility shift was observed in 22 of 60 patients, and their
genomic DNA were analyzed by the direct sequence method and using
cloned ssDNA. Nine of these had missense mutations in the collagenous
domain (in exons 39, 37, 31, 29, 28, 27, 21, 20,19). Eight of these mutations
were observed in a codon of glycine residue . Two were altered to arginine,
two to valine, two to glutamic acid and two to aspartic acid. The other
missense mutation was a change from isoleucine to serine in a interruption
region. Five patients had small size base deletions and one had a 4 bp
insertion resulting in frameshift (in exons 49, 41, 19, 14, 13). Three had a
splice site mutation (in exons 49,47,27). One had a nonsense mutation (in
exon 17). These mutations seemed to be pathogenic, but the phenotype,
which includes extrarenal manifestations, can vary with respect to both
expression and severity. The remaining mutations were three silent ones
(in exons 19,39,46). In addition , major gene rearrangement seemed to be
rare in Japanese AS patients .
Alport syndrome (AS) has emerged as an important hereditary
disorder of progressive nephritis, and is characterized by recurrent
hematuria and progressive renal failure associated with sensori-
neural deafness and ocular abnormalities [1, 2]. AS is classified as
juvenile type [development of end-stage renal disease (ESRD)
before 31 years of age], or adult type (ESRD after 31 years of age)
based on the criteria of Atkin and Gregory [3]. This disease
primarily is linked to the X chromosome [4], but autosomal forms
have been reported [5]. The X-linked form is associated with
mutations in the COL4A5 gene that encodes the 0'5 (IV) collagen
chain. The gene is approximately 250 kb length and divided into
51 exons by 50 introns, producing about 6.5 kb mRNA [6]. The
entirely translated product has 1,658 amino acid residues, which
consist of a signal peptide from the N-terminal residue to the 26th
residue , and a 1430 residual collagenous domain having 22 short
non-collagenous domains (interruption region) and a 229-residual
C-terminal non-collagenous (NC1) domain [7]. The COL4A5
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gene mutations may cause structural and functional defects of the
type IV collagen molecule. To date there have been many reports
of various kinds of mutations, including one point mutation and
deletion or insertion of large or small nucleotide sequences
[8-12]. The detection of a mutation of this large COL4A5 gene, of
which the full sequence has not yet been established, is laborious,
and 90% of the mutations are expected to be subtle ones. Therefore ,
to investigate the characteristic features of the COL4A5 gene
mutations in Japanese AS patients, we employed the PCR-SSCP
method [13] to detect the mutations and screened all the exons
from 1 to 51.
Methods
Patient materials
Sixty unrelated Japanese AS patients (47 males and 13 females)
were recruited for this study. In making a diagnosis, we modified
the criteria proposed by Flinter et al [2]. All patients had
characteristic electron microscopic change of the GBM in their
renal biopsies [14], and all the patients fulfilled at least one of the
three following criteria: (1) a positive family history of hematuria
with or without renal failure; (2) diagnostic ophthalmic signs; (3)
high-tone neurosensory deafness. Eight patients had been
recruited for a previous report [10]. One of these was known to
have a point mutation in exon 49. The other 52 patients came
from the multiple institutions from all over Japan (The mem-
bers of Japanese Alport Network are listed in the Acknowledg-
ments). Two patients also had Epstein syndrome. No patients
had esophagealleiomyomatosis. Peripheral blood was collected
by a vaccutainer with heparin (or EDAT-2Na) as an anticoag-
ulant. Genomic DNA was extracted from white cells according
to the usual method [15].
PCR-SSCP analysis
Screening for mutations was done by the single strand confor-
mation polymorphism (SSCP) method [13] after amplification of
each exon by the polymerase chain reaction (PCR) method . The
primer sets used here were designed on the basis of the sequence
reported for 51 exons [16, 17], which are shown in Table 1. All
primer sets were designed on the intron sequences adjacent to all
the exons, except for exons 2 and 37. Since the intron sequences
data of exons 2 and 37 were not available, those primer sets were
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Table 1. Oligonucleotide primer used for SSCP analysis
Primer A Primer B
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TCTAGAGCTCTAGCTCTCTCCATA
GGATCCGCTTGCTATGGGTGTTC
CTGCAGTCATTCTCATTTAATTGC
CTGCAGAAAAATATTGCATTTTTCA
CTGCAGGATTTTATTTCTTCTTATA
CTGCAGTGTTATGTCGCTTTTCAA
CTGCAGTTATTTTTAACTCCTTCT
CTGCAGCCTTTTCTTTTTAATAATA
CTGCAGCCATTGATGGCTTCTT
CTGCAGCTTTACTCACTTTATAAC
CTGCAGTTTTGTCTTCTCTTCTTA
CTGCAGATGGAAACTTCTCTCTCC
CTGCAGTTATTTTATCTTGCAAAC
CTGCAGTTCCCCTACTACTGCA
CTGCAGAACTATTTTTATGTGTAC
CTGCAGCATTTCTTTGTATCCTAT
CTGCAGCTATCCTCTATGTTTTA
CTGCAGTTTACAATTGCATTGAAC
CTGCAGI I I I I ICTTTGGTAATAAA
GGATCCGATCACIIIIIIGAATCTT
CTGCAGTCCTTTCTTTATCTTACTC
CTGCAGTGTTATTATGATTTCACT
AAGCTTACGTTATTGTGT
CTGCAGTTTTTCCTTACTCATTTC
CTGCAGTTAAACTTTTCCCTTTTT
CTGCAGTGATTTACTCTTGCTTTC
CTGCAGATAACTGCTGTTTCTCCA
CTGCAGAAATGACTTATCATTTTAC
CTGCAGTTGTCATGTGTATGCTCA
CTGCAGACTGTATTTATTTCTTAA
CTGCAGATTGATATTGTATTAACTAG
CTGCAGCTTATTGATATTCTTCAA
CTGCAGATATTGTGTTTTCACACAC
CTGCAGTAACTTGCCTCTTCTACTC
CTGCAGGTCTTAATTTTACCAATTTGA
CTGCAGTATATATCACATATTTTCAAC
CTGCAGGGTGAGCCTGGTCTGC
CTGCAGTTAAATTGAGCTCTTTACTC
CTGCAGTGTAACCTGCTGTATCAAT
CTGCAGTTGTTTTGTTTTGTACTCTGA
CTGCAGTATACTTTACTTTC
CTGCAGAAATGTCGTCATTTGCTGTG
CTGCAGTTTGTAACATTAATGATTTTAT
CTGCAGAAACTGTATGTACCTTCTGT
CTGCAGCCCTTCAAATTTGTGTGTTTTG
CTGCAGGAATGCCTCATTCTTTTCC
CTGCAGTATACTGATTATTTCGTGGA
CTGCAGCTTTACTGTTTTCTCTCCAA
CTGCAGATGTTCCTTCTCCTTTTCC
CTGCAGTTGCGGCACATTTTTCCTT
CTGCAGGATCTGATTGTCTTA
GGATCCAGGGGAGGAAGGACTTAC
AAGCTTCTTTTCCCCTTTTATGCC
AAGCTTGTTGGCAACATGATAC
AAGCTTATAGAGAAAATACTACTT
AAGCTTAAGTGAAATGCTACTTA
AAGCTTATTAAATGGATGGATCTC
AAGCTTTCCCAAATTTTATAACTT
AAGCTTAGAATGAGATGCTTAC
AAGCTTAATCACTGGATACTTAC
AAGCTTAATTAAACAACACAGCTT
AAGCTTATAAAGAAAAAGAAAATTAC
AAGCTTAGCTCTCTTTCTTTACTCA
AAGCTTCTTCCTCCCTACTTA
AAGCTTAGCACTTTAGGTACTTAC
AAGCTTTTAGCAGTTACATCAC
AAGCTTAAAGAACCTTAGCTACT
AAGCTTCAAAGTATTAAAATTCTTA
AAGCTTACTAAAAAAAAAAAACTTAC
AAGCTTATAAATGCAATCTCATTT
AAGCTTAGGAGAAAAATATAGCTTA
AAGCTTATATGTTTGGAGATCAAAC
AAGCTTTACCCTGAGGCATAA
GGATCCTGTAAAATGCCTTCCTTC
AAGCTTAAAATATCAAACCAACTC
AAGCTTCAAAACACAGTAAACTT
AAGCTTGAAATAAATTCCTCACATA
AAGCTTTGCTACCCATTCCAACA
AAGCTTTAAAGAAAAATGTCCCAG
AAGCTTGCAGTGACAGCCTCCA
AAGCTTCACATTTATCTAATCT
AAGCTTGAAAACTTTAAACAAATTAC
AAGCTTCAGCAAACCTTGATTAT
AAGCTTTTCATAAATAAATTCATTCAC
AAGCTTCAATTGCTACAAATGGCCT
AAGCTTCTAAATATTTGGAAGATTTTC
AAGCTTATGTGCCTAAAACTATATG
AAGCTTCTGGGAATCCAGGAAGG
AAGCTTACAGCAAACTGTTATTTTTC
AAGCTTGGAAAAATGAAAAACTACAGC
AAGCTTGTTTAGCATGTTTTATTAAGG
AAGCTTATTCTCCTACCACT
AAGCTTCTCATCAGATATCTACTTCC
AAGCTTAGTTTAATATAAAGGGAAAC
AAGCTTGGTATAACTATCTTCAGGAA
AAGCTTAATGATAATAAAGATGATCTGCA
AAGCTTTCCACCAACAGCATGTTTT
AAGCTTCAGTAGGAAATTAGATATTG
AAGCTTAAGTCACAGCTAAATCAATG
AAGCTTGACAAATGCAAGGAAGAGT
AAGCTTGGACCTGAATTAAAGCTATA
AAGCTTACACAAAAGGAATTC
All primers are given in 5' to 3' orientation.
designed on those exon sequences. Each primer was designed to
produce the restriction endonuclease sites for subcloning into the
sequence vector, M13 mp18 or mpl9.
PCR-SSCP analysis was done as follows: The reaction mixture
(5 ILl), containing 50 ng of genomic DNA, reaction buffer, dNTPs
solution, and 1 pmol of each 33P-labeled primer prepared by
reaction of T4 polynucleotide kinase (Gibco BRL Life Technol-
ogies, Inc., NY, USA) at 37°C for 30 minutes, and 0.02 units of
thermostable enzyme Taq polymerase (Perkin-Elmer-Cetus Inc.,
Norwalk, CT, USA), was placed on a Programmable Thermal
Cycler (MJ Research Funakoshi Inc., Tokyo, Japan) for 30 cycles
of denaturation at 94°C for five minutes, annealing (temperature
and time are shown in Table 2) and primer extension at nocfor
one minute, and for additional extension reaction at nocfor five
minutes. After incubation of the amplified DNA in BPB-form-
amide solution in boiling water at lOO°C for five minutes, the
DNA was electrophoresed on 5% polyacrylamide gel containing
5% glycerol at 500 volts (constant) for 15 hours. The gel was then
dried to fixon filter paper and the DNA band was analyzed by an
Imaging Analyzer (BAS 2000, Fujix Inc., Tokyo, Japan). The gel
was also exposed on X-ray film for six to seven days to obtain an
autoradiogram.
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Table 2. Conditions used for SSCP analysis
Primer A Primer B Annealing Product
restriction restriction temperature; size
Exon enzyme enzyme extension time (fragments)
1 Xbal BamHI 50°C; 1 min 219
2 BamHI HindIII 5SOC; 1 min 78
3 Pst! HindIII 43°C; 1 min 148
4 Pst! HindIII 4SOC; 1 min 103
5 Pst! HindIII 45°C; 1 min 103
6 PstI HindIII 50°C; 1 min 121
7 Pst! HindIII 45°C; 1 min 112
8 Pstl HindIII 45°C; 1 min 85
9 Pstl HindIII 50°C; 1 min 136
10 Pst! HindIII 43OC; 1 min 120
11 PstI HindIII 50°C; 1 min 93
12 PstI HindIII 52°C; 1 min 100
13 PstI HindIII 45°C; 1 min 151
14 Pst! HindIII 50°C; 1 min 110
15 Pst! HindIII 45°C; 1 min 115
16 Pst! HindIII 45°C; 1 min 103
17 Pst! HindIII 45°C; 1 min 112
18 Pst! HindIII 45°C; 1 min 99
19 Pst! HindIII 4SOC; 1 min 191
20 BamHI HindIII 45°C; 1 min 233
21 Pst! HindIII 52°C; 1 min 143
22 Pst! HindIII 45°C; 1 min 151
23 HindIII BamHI 55°C; 1 min 193
24 Pst! HindIII 4SOC; 2 min 250
25 Pst! HindIII 45°C; 1 min 226
26 Pst! HindIII 52°C; 1 min 151
27 Pst! HindIII 50°C; 1 min 164
28 PstI HindIII 4SOC; 1 min 156
29 PstI HindIII 50°C; 1 min 207
30 Pst! HindIII 45°C; 1 min 170
31 Pst! HindIII 50°C; 1 min 227
32 Pst! HindIII 45°C; 1 min 147
33 Pst! HindIII 50°C; 1 min 223
34 Pst! HindIII 52°C; 1 min 177
35 Pst! HindIII 52°C; 1 min 168
36 Pst! HindIII 50°C; 1 min 211
37 Pst! HindIII 5SOC; 1 min 145
38 Pst! HindIII 52OC; 1 min 150
39 Pst! HindIII 52°C; 1 min 165
40 Pst! HindIII 60°C; 1 min 119
41 PstI HindIII 43°C; 2 min 247
42 Pst! HindIII 55°C; 1 min 211
43 Pst! HindIII 50°C; 1 min 162
44 Pst! HindIII 52°C; 1 min 144
45 Pst! HindIII 55°C; 1 min 199
46 PstI HindIII 5SOC; 1 min 171
47 Pst! HindIII 55°C; 2 min 286
48 Pst! HindIII 55°C; 2 min 252
49 Pst! HindIII 55°C; 1 min 188
50 PstI HindIII 55°C; 2 min 251
51 PstI HindIII 45°C; 1 min 153
Product and fragment sizes are given in base pairs.
Direct sequence analysis
The nucleotide sequence of all PCR products revealed by the
abnormal mobility shift on PCR-SSCP analysis was determined by
the direct sequencing method using the dsDNA Cycle Sequencing
System (Gibco BRL). A reaction mixture (4 p,l) containing 50 ng
of the template PCR product purified by usc of Prep-A-Gene
(BioRad Laboratories) after 2.0% NuSieve agarose gel (FMC Bio
products) electrophoresis, 1 pmol of 33P-labeled primers (Table
1), 5 units of Taq polymerase (Gibco BRL), and the reaction
buffer was placed on a Thermal Cycler for 15 cycles of denatur-
ation at 95°C for 15 seconds, annealing at 55°C for 15 seconds and
extension at 70°C for 45 seconds, followed by an additional 15
cycles of heating at 95°C for 15 seconds and extension reaction at
70°C for 45 seconds. The product dissolved in formamide (5 p,l)
was heated at 95°C for three minutes, and electrophoresed on
5%-polyacrylamide gel containing 7 M urea at 2000 volts (con-
stant) for three hours. After the gel was washed with a 10% acetic
acid-lO% methanol solution and dried to fix on the filter paper,
an autoradiogram was obtained using the Imaging Analyzer.
Sequence analysis through cloning
To confirm the nucleotide mutation observed in the direct
sequencing the cloned ssDNA was analyzed. The amplified DNA
digested with appropriate restriction enzymes was electropho-
resed on 2% NuSieve agarose gel(FMC Bio products), and the
proper DNA fragment was removed and purified by use of
Prep-A-Gene (BioRad Laboratories Inc.). The DNA was ligated
into phage vector M13 mp18 or mp19, which had been digested
with the same enzymes and transfected into competent JM109
bacterial cells by an E. Coli Pulser (BioRad Laboratories Inc.).
The bacterial preparation was spread on a YT agar plate contain-
ing IPTG and X-gal to select the colorless plaques. Colorless
plaques were picked up and incubated in SOB culture medium at
37°C for five to six hours, and the ssDNA was prepared by the
standard method. Sequencing was done by the dideoxy chain
terminating method [17] with the 7-deaza-dGTP Sequencing Kit
Version 2.0 (USB, Life Science Inc., IL, USA); then gel electro-
phoresis was performed in the same manner as the method
described for direct sequencing, and the synthesized and the
universal oligonucleotides were used as a sequencing primer.
Results
PCR-SSCP analysis of the COL4A5 gene of 60 unrelated
Japanese AS families showed the presence of 22 different muta-
tions (Table 3). In all patients, the amplified DNA products of all
exons from 1 to 51 were obtained. The nucleotide sequence of
these mutations were determined by direct sequencing of the PCR
product purified by the electrophoresis-extract method, followed
by sequencing of the cloned ssDNA to confirm it in detail. As
listed in Table 3, 19 of these mutations were expected to be
functionally significant ones. There were four mutations causing a
frameshift, five involving splice site alteration, one nonsense
mutation, nine having a missense mutations and three having
silent mutations (Fig. 1).
Insertional and deletional mutations
Six new types of nucleotide insertion and deletion mutations
were determined: (1) deletion of a dinucleotide (AG) from codon
254 (GAG; nucleotide 961 to 963) of exon 13, which caused a
frame shift to produce stop codon (TAA) at codon 263; (2)
deletion of 7 nuclcotides (GGGACTI) from the sequence be-
tween intron 13 and exon 14 (acceptor splice site), which probably
influences the normal splicing process; (3) deletion of mononu-
cleotide (A) from codon 359 (GAA) in exon 19, which caused a
frameshift; (4) deletion of 52 nucleotides from sequence codon
1237-1255 (nucleotide 3912-3963) in exon 41, which caused a
frameshift to produce a stop codon at 14 codons further on (Fig.
2); (5) deletion of 32 nucleotides from the sequence between
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Table 3. Consequences of mutations and polymorphisms in the
COL4A5 gene on the a5(IV) collagen chain in different
Alport kindreds
Amino acid
Mutation change Exon Predicted mutation
Insertion/Deletion
962/de1AG 13 Frameshift from Glu-254
983-l/deI7 14 Acceptor splice site mutation
1274/deIA 19 Frameshift from Glu-359
3912/de152 41 Frameshift from Trp-1249
3959/ins4 41 Frameshift from Arg-1253
4891-3/deI32 49 Acceptor splice site mutation
Missense
1350G->A Gly383Asp 19 Disrupts Gly-Xaa-Yaa repeats
1599G->A Gly466Glu 21 Disrupts Gly-Xaa-Yaa repeats
2253G->T Gly684Vai 27 Disrupts Gly-Xaa-Yaa repeats
2420G->A Gly740Glu 28 Disrupts Gly-Xaa-Yaa repeats
2517G->A Gly772Asp 29 Disrupts Gly-Xaa-Yaa repeats
2756G->A Gly852Arg 31 Disrupts Gly-Xaa-Yaa repeats
3512G->T Glyl104Vai 37 Disrupts Gly-Xaa-Yaa repeats
3746G->C Gly1182Arg 39 Disrupts Gly-Xaa-Yaa repeats
1535T->G Ile444Ser 20 Unknown
Nonsense
1175G->T Gly325Term 17 Truncated protein
Splice site
2348G->C 27 Donor splice site mutation
4712+1G->C 47 Donor splice site mutation
5005G->C 49 Donor splice site mutation
Silent
1279G->C Gly365Gly 19 No change
3715A->G Glull71Glu 39 No change
4441C->T Leu1413Leu 46 No change
Nucleotide and amino acid numbering are according to the system of
Zhou et al [17].
intron 48 and exon 49 (acceptor splice site), which probably also
influences the normal splicing process; and (6) insertion of a
tetranucleotide (GGCA) between the first and second nucleotide
of codon 1253 (AAC; Asn) of exon 41, which resulted in the
production of a stop codon in codon 1262 (TAG) (Fig. 3). These
deletion or insertion mutations are all expected to cause changes
in the reading frame and the production of non-functional
protein.
Nonsense mutation
One nonsense mutation, a change from G to T of the first base
of codon 325 (GGA; Gly) in exon 17, was found. This mutation
might cause a truncation of 19% of the protein translated from
the gene.
Splice site mutations
Three splice site mutations were determined: (1) a change from
G to C at nucleotide 5005 in exon 49, which has been previously
described [10]. This change converted a codon of methionine
residue to a codon of isoleucine residue at codon 1601 and also
altered the splicing process. (2) There was a change from G to C
at nucleotide 2348 in exon 27, which converted a codon of glycine
residue to a codon of arginine residue at codon 716. Finally, there
was (3) a change from G to C at the first base of the donor splice
site sequence of intron 47 (4712+ 1). The last two mutations were
expected to influence the normal splicing process and to alter the
conformation of the protein molecule or result in premature
termination of translation.
Missense mutations
Nine different missense mutations had a nucleotide change in
the sequence encoding a glycine residue, causing amino acid
substitutions of Gly-s-Asp {GGC-..GAC at codon 383 (nucleo-
tide 1350) in exon 19 and GGT-..GAC at codon 772 (nucleotide
2517) in exon 29}, of Gly-s-Glu {GGA-..GAA at codon 446
(nucleotide 1599) in exon 21 and GGG-..GAG at codon 740
(nucleotide 2420) in exon 28}, of Gly-s-Val {GGA-..GTA at
codon 684 (nucleotide 2253) in exon 27 and GGT-..GTI at codon
1104 (nucleotide 3512) in exon 37 (Fig. 4)} and of Gly-s-Arg
{GGA-..AGA at codon 852 (nucleotide 2752) in exon 31 and
GGT-..CGT at codon 1182 (nucleotide 3746) in exon 39}.
The other was a missense mutation with a nucleotide change in
sequence encoding a isoleucine residue, causing amino acid
substitution of Ile-..Ser{ATI-..AGT at codon 444 (nucleotide
1535) in exon 20}. Unlike the other mutations, this missense
mutation was detected in three of 60 families. In addition, these
three families were revealed to all have three silent mutations,
which are described below.
Silent mutations
Three silent mutations were observed as listed in Tables 3 and
4. These mutations were nucleotide changes at the third base of
codon 365 {GGG(Gly)-..GGC(Gly) at nucleotide 1279} in exon
19, of codon 1171 {CAA(Glu)-..CAG(Glu) at nucleotide 3715}
in exon 39, and of codon 1413 {CTC(Leu)-..CTI(Leu) at the
nucleotide 444l} in exon 46. These changes did not cause amino
acid substitution, and they were expected to be a kind of poly-
morphism, although they were observed on the genes from the AS
patients. All three patients who had Ile444Ser also had two silent
mutations (1279G-..C and 3715A-..G). One of the three patients
who is indicated "Ile444Ser*(I)" in Table 4, also had the remain-
ing silent mutation (4441C-..T).
Discussion
Our initial screening for mutations in 60 Japanese AS patients
using the PCR-SSCP method identified 22 different mutations in
the COL4A5 gene. These included one small size insertion and
five deletions, nine missense, one nonsense, three splice site and
three silent mutations. This multicenter study, which included
contributions by both the departments of pediatrics and internal
medicine, recruited AS patients from all over the country. There-
fore, our finding seemed to represent the spectrum of the
COL4A5 gene mutations in Japanese AS population.
The mutations of these patients were equally distributed in
their location. Each family had its own mutation except for
Ile444Ser and three silent mutations. There were no families with
two or more mutations in the COL4A5 gene except for the three
families that had silent mutations and Ile444Ser (Tables 3 and 4).
These findings seem to be similar to those made in Caucasian
populations and noted in numerous previous reports [8, 19, 20].
The COL4A5 gene mutations in AS are classified into three
types. The first type is a mutation involving large gene deletions
that result in the complete absence or destruction of a large
portion of the a5(IV) chain. In our study, no mutation was
detected with such a large deletion or rearrangement. Only one
Japanese family with a large gene deletion at the 3' end of the
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I
Signal peptide Collagenous domain NC - domain
Fig. 1. Location of the mutations within the
protein product of the COL4A5 gene. The details
of the mutations are listed in Table 3. The
signal peptide (residues 1 to 26) is indicated by
the black square. The Gly-X-Y repeat
containing collagenous domain is indicated by
the white squares with the 22 non-collagenous
interruptions depicted by the shaded squares.
The C-terminal end NC domain (residues 1475-
1685) are also indicated by a shaded square.
This illustration is based on the illustration of
Triggvason et al [8].
A B
GTAC GTAC
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Patient
-3964
-3911
Wild type
Fig. 2. A The PCR products of exon 41 of a
male patient and his family. Father (lane 1),
mother (lane 2), the patient (lane 3), younger
brother (lane 4), healthy control (lane 5),
<l>XI74/HaeIII digest DNA marker (lane M).
The expected size of PCR product is 247 bp.
The PCR products of the patient and his
brother are 195 bp in size. Their mother's PCR
products are 247 bp and 195 bp, indicating that
she is heterozygous. Arrows indicate the
affected members. B. Sequence analysis through
cloning of exon 41 DNA of patient and a male
control. The sequences show deletion of 52
nucleotides from nucleotide 3912-3963. Direct
sequence analysis showed the same result (data
not shown).
B
) 0
1 234 5
P u nt Wild ty
Fig. 3. A Mobility shifts are observed on PCR-SSCP analysis of DNA from
the exon 41. Male patient (lane 1); Patient's brother (lane 2); Other lanes
represent a control individual and other AS patients exhibiting the normal
mobilitypattern. B. Sequence analysisthrough cloning of exon 41 DNA of
patient and a male control. The sequence shows insertion of a tetranucle-
otide (GGCA). Direct sequence analysisshowed the same result (data not
shown).
COL4A5 gene has been identified [21]. In Caucasian populations,
the rate of rearrangement is thought to be around 10 to 16% [20,
22]. Our results and another Japanese study together may indicate
that major rearrangement of the COL4A5 gene is possibly not so
frequent. Including the literature written in Japanese, there have
been no cases of AS complicated by esophagealleiomyomatosis in
Japan. Most such cases have been shown to have a large gene
deletion in the 5' end of the COL4A5 gene through the COL4A6
gene [23-25]. Therefore, a paucity of esophagealleiomyomatosis
may be explained by the low frequency of large deletion in
Japanese AS patients.
The second type is a mutation resulting in truncated protein
such as a shortened 0'5(IV) chain. These mutations involve not
only small deletions and insertions, but also nonsense mutations
and splice site mutations. It is noteworthy that by frameshift, this
type of mutation affects the carboxyl terminal NCI domain, which
plays a role of a hinge for a chain monomers. In addition, the
truncated chains were expected to affect post-translational mod-
ification, triple helix formation and secretion to the extracellular
space. As a result, they would destroy the network of the
basement membrane structure. The clinical features of AS with
this type mutation will be discussed later in this paper, comparing
with the third type of mutation.
The third type is a single base mutation that can be expected to
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Fig. 4. A PCR-SSCP analysis of exon 37 in AS
patients and a control. The mobility shift
corresponding to the AS patient are apparent
in lane 8. Other lanes represent control
individual and other AS patients exhibiting the
normal mobility pattern. B. Direct sequence
analysis of exon 37 DNA of patient and his
mother. The patient's sequence shows a
nucleotide change G to T (nucleotide 3512) in
exon 37 causing amino acid substitution of
Gly~Val at codon 1104. His mother is shown
to be heterozygous.
Table 4. Mutations in the COL4A5 gene and phenotypes in Alport syndrome
Phenotype
Genoty~ Hematuria ESRD GBM Ocular FamilyProteinuria onset splitting Deafness abnormality history Sex
962/de1AG + + J + M
983-l/deI7 + + A + + M
1274/de1A + + ND + ND ND + M
3912/de152 + + ND + + M
3959/ins4 + + ND + + + M
4891-3/deI32 + + A + F
Gly383Asp + + J + + + M
Gly466Glu + + ND + + + M
Gly684Vai + + A + + (+) + F
Gly740Glu + + J + ND ND ND M
Gly772Asp + + J + + M
Gly852Arg + + ND + + M
Gly1104Val + + ND + + M
Gly1182Arg + + J + + (+) + M
I1e444Ser(1)" + + J + + (+) + F
I1e444Ser(2)" + + J + + M
I1e444Ser(3)" + + ND + F
Gly325Term + + ND + + M
2348G~C + + J + + (+) + M
4712+1G~C + + J + + M
5005G~C + + J + + M
Abbreviations are: J, juvenile; A, adult; ND, patient's status for this feature has not been determined because they are too young for the evaluation
at present; (+), the retinal abnormalities (not the lenticonus).
a I1e444Ser was noted in three unrelated patients.
render the a5(IV) chain malfunctional. A repetitive sequence in
which every third amino acid is a glycine (Gly-Xaa-Yaa) is
required for proper assembly of the collagen triple helix, because
this is the only amino acid small enough to fit into the center of
the triple helix [8]. The amino acid residues in the Xaa-Yaa
positions are located on the outside of the triple helix, and if these
amino acids contain a side chain, they are directed out of the helix
structure. In our study, 40% (8 of 20) of the mutation detected
were glycine substitutions in the collagenous domain. Glycine was
changed to arginine, valine, glutamic acid or aspartic acid. These
converted amino acids are bigger than glycine and have a polar.
These mutations were expected to interfere with triple helical
formations and other type IV chains.
Boye et al reported nine glycine substitutions in the collagenous
domain [20]. Among them, two were located in exon 31
(Gly869Arg and Gly872Arg). We considered comparison of the
clinical phenotype of the AS patients with a similar genotype to be
worthwhile. Both of Boye et al's patients, whose the glycine
substitutions were in exon 31, had hearing loss, whereas our
patients (Gly852Arg) and affected family members, whose muta-
tion is also in exon 31, have normal hearing activity (Tables 3 and
4). The pathogenesis of deafness in AS is not well understood.
Accumulation of such genotype and phenotype analysis mayprovide
clues to identification of the mechanism of deafness in AS.
We detected a single base mutation in which serine was
substituted for isoleucine in the eighth interruption (Ile444Ser).
This missense mutation was detected in three different families.
There has been no report of such a missense mutation in
interruption of the collagenous domain or of a mutation that was
shared by more than two families. Since the role of the eighth
interruption in the collagenous domain is unknown, further
studies are needed to clarify the significance of this mutation.
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We have presented the clinical data of male patients for 16 of
18 mutations (Table 4). This provides important information
regarding the biological function of the gene product, as well as
new clinical insights. Ten of our patients have mutations which are
expected to destroy the functional NCI domain (insertion, dele-
tion, nonsense or splicing mutation). Four of those ten patients
have a juvenile type AS. Generally, deletions within the COL4A5
gene are thought to be associated with juvenile type, deafness and
eye signs, while missense mutations and splicing errors are less
likely to be associated with juvenile renal failure [26]. Our data,
however, indicated that most patients except for one with mis-
sense mutations developed ESRD earlier than those with muta-
tions that are expected to destroy the functional NCI domain
(Table 4).
In addition, three cases with the same amino acid substitution
showed different phenotypes. The aspartic acid substitutions were
Gly383Asp and Gly772Asp. A patient with Gly383Asp is charac-
terized by a deafness, whereas a patient with Gly772Asp is
characterized by normal hearing activity. The valine substitutions
were Gly684Vai and Glyl104Vai. A patient with Gly684Vai is
characterized by a deafness with retinal abnormalities, whereas a
patient with Glyll04Vai is characterized by normal hearing
activity without retinal findings. The arginine substitutions were
Gly852Arg and Gly1l82Arg. A patient with Gly852Arg is charac-
terized by normal hearing activity without retinal abnormalities,
whereas a patient with Gly1l82Arg is characterized by a deafness
with retinal abnormalities. Renal function and extra-renal mani-
festations, such as deafness and ocular lesions, can vary both with
respect to presence and severity even within a family.
Since it is difficult to predict the consequences of mutations in
the COL4A5 gene in AS, as discussed in this article, in addition to
the type of mutation several other factors should be considered.
For example, alternative splicing may contribute to GBM impair-
ment and renal failure progression [27], and Iyonization has also
been reported to negatively influence the clinical course of female
patients [10, 28, 29]. The variability that remains may be due to
factors other than the mutation. For example, dietary protein
intake, pregnancy, exercise and physical stress can also modulate
the phenotype.
Our study included two patients with Epstein syndrome [30], in
whom we did not identify any mutations. There have been no
COL4A5 gene mutation reports of patients with Epstein syn-
drome in the literature. This disorder is categorized in the entity
of Alport syndrome (MaQusick*15365) and shows similar char-
acteristic GBM change. To determine whether or not Epstein
syndrome should be differentiated from AS, additional genetic,
histologic and clinical research seems to be necessary.
Besides the paucity of esophageal leiomyomatosis, patients in
the literature and the patients studied here show several addi-
tional characteristic features in Japanese AS. Primarily because
renal transplantation is still restricted for the treatment of ESRD
in Japan, there are no reports of Japanese AS patients with
transplants who have developed anti-GBM antibody nephritis
among our cases or in the literature, whereas many cases have
been noted in Caucasian populations [9, 19, 31-33]. AS cases
complicated by lenticonus are also quite rare in Japan. In the
literature, while Govan reported a rate of lenticonus of 50% (8 of
16) [34] and Jacobs et al reported one of 10% (2 of 20) [35],
Takeda et al reported one of 0.61% (1 of 163) in Japanese
patients [36]. The mechanisms of anti-GBM antibody nephritis
and lenticonus in AS are not well understood. However, in the
Third International Workshop on AS (Erlangen-Nurmberg, 1994)
in a discussion of a phenotype versus genotype correlation, Prof.
Gregory (Salt Lake City, USA) reported, after reviewing numer-
ous mutation reports, that about 50% of AS patients with
complications anti-GBM nephritis or lenticonus had large size
deletions of the COL4A5 gene. These findings may possibly
explain the paucity of anti-GBM antibody nephritis and lenticonus
in Japanese AS patients. Antignac suggested that other factors, in
addition to the genetic defect, are implicated in the occurrence of
this alloimmunization for the development of anti-GBM nephritis
[22].
Ocular lesions were identified in 13% (8 of 60) of the patients
in our study (the lenticonus in one patient and retinal abnormality
in seven patients). Jacobs et al reported the rate of this ocular
complication to be 25% (5 of 20) [35], and Takeda et al reported
it to be 6.1% (10 of 163) [36]. Teekhasaenee et al reported the
ocular abnormalities of AS in Thailand [37], describing the higher
incidence of lenticonus to be 47% (8 of 17) and retinal flecks to be
35% (6 of 17). Among the patients in whom the mutation was
identified in our study, there were four patients with retinal
abnormalities 18% (4 of 22). Three of them had a missense
mutation and the other had a splicing site mutation. It remains to
be determined how the mutation pattern contributes to this ocular
complication. The genotyping of COL4A5 gene in the Thai AS
patients may provide some clue to identify the pathogenesis of the
ocular lesion of the disease.
We detected three de novo type AS (13%; 3 of 22). Tryggvason
et al reported absence of a family history in about 15% of their
cases [8]. In Japan, Uraoka et al estimated the incidence of new
mutations to be 17.2% in a nation wide clinical survey [38].
Therefore, there appears to be no difference between Caucasian
and the Japanese in the rate of new mutations of the COL4A5
gene.
In this study, the COL4A5 gene mutation could not be identi-
fied in 38 of 60 patients. Because modified diagnostic criteria were
employed to avoid the exclusion of sporadic cases, it was possible
that some autosomal AS cases were included in our study. There
may be other mutations in the intronic region, in the cis-element
or in the COL4A6 gene. The ability of the SSCP to detect
mutations should always be considered. We carried out SSCP
analysis of exons in which the expected size of the amplified
product was over 200 bp. Boye et al emphasized that size was
important for favorable sensitivity of this screening method, and
they were reluctant to perform SSCP analysis of large size exons.
However, we identified four one-point mutations in large exons
20, 29, 31, 47.
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